Iron is biologically essential, but also potentially toxic; as such it is tightly controlled at cell
and systemic levels to prevent both deficiency and overload. Iron regulatory proteins post …

Anemia of Inflammation Anemia of inflammation is a common normocytic, normochromic
anemia associated with systemic inflammation that increases the level of hepcidin and …

Owing to the dysregulation of protein kinase activity in many diseases including cancer, this
enzyme family has become one of the most important drug targets in the 21 st century. There …

Purpose We evaluated the efficacy and safety of momelotinib, a potent and selective Janus
kinase 1 and 2 inhibitor (JAKi), compared with ruxolitinib, in JAKi-naïve patients with …

Summary Background The Janus kinase (JAK) inhibitor ruxolitinib is the only approved
therapy for patients with symptomatic myelofibrosis. After ruxolitinib failure, however, there …

The TANK-binding kinase 1 (TBK1) is a serine/threonine kinase belonging to the non-
canonical inhibitor of nuclear factor-κB (IκB) kinase (IKK) family. TBK1 can be activated by …

Background Janus kinase (JAK) inhibitors approved for myelofibrosis provide spleen and
symptom improvements but do not meaningfully improve anaemia. Momelotinib, a first-in …

Anemia is very common in patients with inflammatory disorders. Its prevalence is associated
with severity of the underlying disease, and it negatively affects quality of life and cardio …

Janus kinase inhibitors (JAKi) approved for myelofibrosis provide spleen and symptom
improvements but do not address anemia, a negative prognostic factor. Momelotinib, an …

JAK inhibitors have been developed following the discovery of the JAK2V617F in 2005 as
the driver mutation of the majority of non-BCR-ABL1 myeloproliferative neoplasms (MPNs) …